The patent approval for Pluri's 3D bioreactor technology is a critical milestone that could significantly enhance the company's competitive edge in the biotechnology and sustainability markets. This technology's ability to efficiently cultivate plant cells for various applications, including healthcare, positions Pluri for potential growth and partnerships, likely positively impacting its stock price in the short term.